IDSA GUIDELINES Bundle (free trial)

Chronic Kidney Disease in HIV-Infected Patients

IDSA GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/418521

Contents of this Issue

Navigation

Page 12 of 15

Table 4. Dosing of Antiretroviral Drugs for HIV-Infected Adults With CKD or ESRD (continued) Antiretroviral Drug and Dosing Category Dosage Comments Non-nucleoside reverse transcriptase inhibitors (NNRTIs) b Nevirapine 200 mg PO bid (aer 2 wks of 200 mg PO daily) Efavirenz 600 mg PO qhs Delavirdine 400 mg PO tid Etravirine 200 mg PO bid Rilpivirine 25 mg PO daily Protease inhibitors (PIs) b Indinavir 800 mg PO bid (in combination with ritonavir 100 mg bid) Saquinavir 1000 mg PO bid (in combination with ritonavir 100 mg bid) Nelfinavir 1250 mg PO bid or 750 mg tid Fosamprenavir 1400 mg PO daily (in combination with ritonavir 100-200 mg daily) OR 700 mg PO bid (in combination with ritonavir 100 mg bid) Ritonavir (used in combination with a second PI as a pharmacokinetic enhancer) 100-400 mg daily Lopinavir/ritonavir 400 mg/100 mg PO bid OR 800 mg/200 mg PO daily. LPV trough lower in HD (use with caution in PI-experienced patients) Atazanavir 400 mg PO daily OR 300 mg PO daily (in combination with ritonavir 100 mg PO daily). Avoid unboosted ATV in HD. Avoid boosted ATV in treatment- experienced patients on HD. Darunavir 800 mg PO daily (in combination with ritonavir 100 mg PO daily) OR 600 mg PO bid (in combination with ritonavir 100 mg bid) 11

Articles in this issue

Archives of this issue

view archives of IDSA GUIDELINES Bundle (free trial) - Chronic Kidney Disease in HIV-Infected Patients